BIOVIE INC. DL-,0001 Logo
US09074F2074

BIOVIE INC. DL-,0001

Ins Portfolio

Kurse werden geladen...

Prognose

Kaufen
  1
Halten
  0
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie 0 / 15
HGI-Strategie 3 / 18
Levermann-Strategie -5 / 13
Powered by aktien.guide

News

  • Foto von BioVie Inc. Announces Closing of Public Offering
    25.09. - 20:05 Uhr

    BioVie Inc. Announces Closing of Public Offering

    CARSON CITY, Nev., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of a previously announced best efforts public offering of 1,360,800 shares of its common stock, pre-funded warrants to purchase 600,000 shares of its common stock (“Pre-funded Warrants”) and warrants to purchase up to 1,960,800 shares of common stock (the "Common Warrants") at a combined public offering price of $1.53 per share (or Pre-funded Warrant) and associated Common Warrant. The Common Warrants have an exercise price of $1.53 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. » Mehr auf globenewswire.com

  • Foto von Crude Oil Gains Over 1%; BioVie Shares Plunge
    24.09. - 18:08 Uhr

    Crude Oil Gains Over 1%; BioVie Shares Plunge

    U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday. » Mehr auf benzinga.com

  • Foto von BioVie Inc. Announces Pricing of Public Offering
    24.09. - 02:26 Uhr

    BioVie Inc. Announces Pricing of Public Offering

    CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on September 25, 2024, subject to satisfaction of customary closing conditions. » Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte BIOVIE INC. DL-,0001 einen Umsatz von 0,00 und ein Nettoeinkommen von 4,60 Mio
(EUR) Juni 2024
YOY
Umsatz 0,00 -
Bruttoeinkommen 53,42k 13,10%
Nettoeinkommen 4,60 Mio 44,86%
EBITDA 4,16 Mio 57,47%

Fundamentaldaten

Metrik Wert
Marktkapitalisierung
8,54 Mio
Anzahl Aktien
7,98 Mio
52 Wochen-Hoch/Tief
53,22 - 0,95
Dividenden Nein
Beta
1,08
KGV (PE Ratio)
0,16
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
0,34
KUV (PS Ratio)
0,00

Unternehmensprofil

BioVie Inc. ist ein Biotechnologieunternehmen im klinischen Stadium, das sich mit der Entdeckung, Entwicklung und Vermarktung von Arzneimitteltherapien in den Vereinigten Staaten befasst. Zu den Produkten in der Pipeline gehören BIV201, das eine klinische Studie der Phase IIa zur Behandlung von Aszites bei chronischer Leberzirrhose abgeschlossen hat, und NE3107, das sich in einer klinischen Studie der Phase III zur Behandlung von Patienten mit leichter bis mittelschwerer Alzheimer-Krankheit und einer klinischen Studie der Phase I zur Behandlung der Parkinson-Krankheit befindet. Das Unternehmen entwickelt außerdem NE3107, das sich in der präklinischen Phase für die Behandlung von multiplem Myelom und Prostatakrebs befindet. Das Unternehmen war früher unter dem Namen NanoAntibiotics, Inc. bekannt und änderte im Juli 2016 seinen Namen in BioVie Inc. BioVie Inc. wurde im Jahr 2013 gegründet und hat seinen Sitz in Carson City, Nevada.

Name
BIOVIE INC. DL-,0001
CEO
Cuong Viet Do M.B.A.
Sitz Carson City, nv
USA
Website
Industrie
Chemikalien
Börsengang
18.09.2020
Mitarbeiter 14

Ticker Symbole

Börse Symbol
NASDAQ
BIVI
🍪

Parqet nutzt Cookies. Erfahre Mehr